{"pmid":32292879,"pmcid":"PMC7141599","title":"The appropriate position of radiology in COVID-19 diagnosis and treatment-current status and opinion from China.","text":["The appropriate position of radiology in COVID-19 diagnosis and treatment-current status and opinion from China.","Chin J Acad Radiol","Xue, Huadan","Jin, Zhengyu","32292879"],"journal":"Chin J Acad Radiol","authors":["Xue, Huadan","Jin, Zhengyu"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292879","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s42058-020-00030-6","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266295715037184,"score":8.233237,"similar":[{"pmid":32238757,"title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","text":["Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).","Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.","J Microbiol Biotechnol","Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun","32238757"],"abstract":["Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19."],"journal":"J Microbiol Biotechnol","authors":["Ahn, Dae-Gyun","Shin, Hye-Jin","Kim, Mi-Hwa","Lee, Sunhee","Kim, Hae-Soo","Myoung, Jinjong","Kim, Bum-Tae","Kim, Seong-Jun"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238757","week":"202014|Mar 30 - Apr 05","doi":"10.4014/jmb.2003.03011","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","coronavirus","outbreak"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352135440400384,"score":83.78813},{"pmid":32304509,"title":"COVID-19 in children: Current status.","text":["COVID-19 in children: Current status.","Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China in December 2019. The outbreak further exploded in Europe and America in mid-March 2020 to become a global health emergency. We reviewed recent published articles and on-line open messages on SARS-CoV-2-positive infants and children younger than 20 years of age. Symptoms are usually less severe in children than in adults. Twelve critically or mortally ill children were found in the published or news reports before April 6, 2020. Vertical transmission from the mother to her fetus or neonate has not been proven definitively. However, six early-onset (<7 days) and 3 late-onset neonatal SARS-CoV-2 infections were found in the literature. We also summarized the presentations and contact information of 24 SARS-CoV-2-positive children announced by the Taiwan Centers for Disease Control. Early identification and isolation, adequate management, prevention, and vaccine development are the keys to controlling the disease spread. Clinical physicians should be alert to asymptomatic children with COVID-19. Multi-directional investigations are crucial in the global fight against COVID-19.","J Chin Med Assoc","Jeng, Mei-Jy","32304509"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China in December 2019. The outbreak further exploded in Europe and America in mid-March 2020 to become a global health emergency. We reviewed recent published articles and on-line open messages on SARS-CoV-2-positive infants and children younger than 20 years of age. Symptoms are usually less severe in children than in adults. Twelve critically or mortally ill children were found in the published or news reports before April 6, 2020. Vertical transmission from the mother to her fetus or neonate has not been proven definitively. However, six early-onset (<7 days) and 3 late-onset neonatal SARS-CoV-2 infections were found in the literature. We also summarized the presentations and contact information of 24 SARS-CoV-2-positive children announced by the Taiwan Centers for Disease Control. Early identification and isolation, adequate management, prevention, and vaccine development are the keys to controlling the disease spread. Clinical physicians should be alert to asymptomatic children with COVID-19. Multi-directional investigations are crucial in the global fight against COVID-19."],"journal":"J Chin Med Assoc","authors":["Jeng, Mei-Jy"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304509","week":"202016|Apr 13 - Apr 19","doi":"10.1097/JCMA.0000000000000323","source":"PubMed","topics":["Prevention","Treatment","Diagnosis"],"weight":1,"locations":["China","America"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664431720393342976,"score":82.96965},{"pmid":32234466,"title":"Coronavirus disease 2019 (COVID-19): current status and future perspective.","text":["Coronavirus disease 2019 (COVID-19): current status and future perspective.","The coronavirus disease 2019 (COVID-19) is derived from Wuhan city, Hubei province of China, has spread quickly in 72 countries to date. COVID-19 is caused by a novel coronavirus SARS-CoV2, previously 2019-nCoV. At present, the newly identified SARS-CoV2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged COVID-19 is urgently needed to elucidate their pathogenic mechanisms and epidemiological characteristics, and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV2 and characteristics of COVID-19, such as etiology, pathogenesis and epidemiological characteristics.","Int J Antimicrob Agents","Li, Heng","Liu, Shang-Ming","Yu, Xiao-Hua","Tang, Shi-Lin","Tang, Chao-Ke","32234466"],"abstract":["The coronavirus disease 2019 (COVID-19) is derived from Wuhan city, Hubei province of China, has spread quickly in 72 countries to date. COVID-19 is caused by a novel coronavirus SARS-CoV2, previously 2019-nCoV. At present, the newly identified SARS-CoV2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged COVID-19 is urgently needed to elucidate their pathogenic mechanisms and epidemiological characteristics, and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV2 and characteristics of COVID-19, such as etiology, pathogenesis and epidemiological characteristics."],"journal":"Int J Antimicrob Agents","authors":["Li, Heng","Liu, Shang-Ming","Yu, Xiao-Hua","Tang, Shi-Lin","Tang, Chao-Ke"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234466","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105951","keywords":["COVID-19","Coronavirus","Pneumonia","SARS-CoV2"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1663352135446691841,"score":71.047356},{"pmid":32221171,"title":"Neuraxial procedures in COVID-19 positive parturients: a review of current reports.","text":["Neuraxial procedures in COVID-19 positive parturients: a review of current reports.","Anesth Analg","Bauer, Melissa E","Chiware, Ruth","Pancaro, Carlo","32221171"],"journal":"Anesth Analg","authors":["Bauer, Melissa E","Chiware, Ruth","Pancaro, Carlo"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221171","week":"202014|Mar 30 - Apr 05","doi":"10.1213/ANE.0000000000004831","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352135164624896,"score":63.36507},{"pmid":32265310,"title":"Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19.","text":["Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19.","Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations.","Eur Respir J","Khoury, Maroun","Cuenca, Jimena","Cruz, Fernanda F","Figueroa, Fernando E","Rocco, Patricia R M","Weiss, Daniel J","32265310"],"abstract":["Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations."],"journal":"Eur Respir J","authors":["Khoury, Maroun","Cuenca, Jimena","Cruz, Fernanda F","Figueroa, Fernando E","Rocco, Patricia R M","Weiss, Daniel J"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265310","week":"202015|Apr 06 - Apr 12","doi":"10.1183/13993003.00858-2020","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663609715832127488,"score":61.389736}]}